管桥医疗创始人兼董事长马立金先生表示："衷心感谢北京市医药健康产业投资基金及各位老股东的信 任与支持。本轮融资既是对我们过去努力的认可，更是对未来发展的期许。管桥医疗将坚持'以临床需 求为导向，以自主创新为驱动'，加快推动更多优质产品落地，助力中国高端医疗器械走向世界，为全 球患者带来更精准、更微创的治疗选择。"在本轮融资的助力下，公司将加大创新投入，以持续构建竞 争壁垒，深化产业合作，不断拓展布局。继续深耕肺血管与呼吸介入领域，为用户在肺动脉栓塞治疗、 深静脉栓塞治疗、颅内狭窄治疗方面提供全周期的解决方案。 管桥医疗是一家专注于高端医疗耗材领域，以研发和生产为主体的高科技医疗器械生产企业。公司坐落 于北京密云经济开发区，建立了完善的符合医疗器械生产质量管理规范（GMP）和ISO 13485标准的质 量管理体系，拥有满足GMP要求的万级洁净生产车间和三个独立的检验洁净间。公司核心团队人员均 具有多年心血管产品研发，质量管理，生产管理和运营经验，公司致力于把优质的医疗器械产品带给广 大医院、医生以及患者，提升行业整体医疗水平，造福患者。 投资界1月8日消息，近日，北京管桥医疗科技有限公司（以下简称管桥医疗）宣布 ...

Core Viewpoint - Changhong Technology (300151) shows a strong upward trend with a 6.48% increase, closing at 14.79 yuan, supported by a positive research report predicting steady growth in both the medical and semiconductor sectors [1] Financial Summary - For Q1 2025, Changhong Technology reported a main revenue of 249 million yuan, a year-on-year increase of 6.7%, while net profit attributable to shareholders decreased by 28.94% to 17.73 million yuan [1] - The company's debt ratio stands at 33.51%, with investment income at -496,100 yuan and financial expenses at 3.43 million yuan, resulting in a gross margin of 24.22% [1] Analyst Ratings - The recent report from Huaxin Securities gives Changhong Technology a "Buy" rating, with projected revenues for 2025-2027 at 1.185 billion, 1.401 billion, and 1.687 billion yuan respectively, and EPS estimates of 0.24, 0.32, and 0.43 yuan [1] - The current price-to-earnings (PE) ratios are projected at 50.7, 38.4, and 28.1 times for the respective years [1] - Over the past 90 days, one institution has rated the stock, with a "Buy" rating [1] Investment Flow - In the last three months, the net inflow of financing reached 20.84 million yuan, indicating an increase in financing balance, while the net inflow of securities lending was 106,900 yuan, also showing an increase in the securities lending balance [1]